

# Carin A Uyl-De Groot

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/386814/publications.pdf>

Version: 2024-02-01

93  
papers

1,326  
citations

361413

20  
h-index

477307

29  
g-index

96  
all docs

96  
docs citations

96  
times ranked

2236  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- $\beta$ 1a Therapy Versus Injectable Interferon- $\beta$ 1a Treatment in Relapsing-Remitting Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2022, 40, 91-108. | 3.3  | 4         |
| 2  | Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals. <i>BMJ Open</i> , 2022, 12, e052186.   | 1.9  | 11        |
| 3  | Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial. <i>Clinical Drug Investigation</i> , 2022, 42, 163-175.   | 2.2  | 3         |
| 4  | Barriers to patient enrolment in phase III cancer clinical trials: interviews with clinicians and pharmaceutical industry representatives. <i>BMJ Open</i> , 2022, 12, e055165.  | 1.9  | 2         |
| 5  | Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.   | 1.6  | 0         |
| 6  | Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare. <i>Value in Health</i> , 2022, , .   | 0.3  | 0         |
| 7  | Comment on: "Premedication prior to PEG-asparaginase is cost effective in pediatric patients with acute lymphoblastic leukemia". <i>Pediatric Blood and Cancer</i> , 2022, 69, e29474.   | 1.5  | 0         |
| 8  | Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer. <i>Translational Oncology</i> , 2022, 20, 101418.   | 3.7  | 3         |
| 9  | The DRUG Access Protocol: access inequality and European harmonisation. <i>Lancet Oncology</i> , The, 2022, 23, e202.  | 10.7 | 3         |
| 10 | Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. <i>Cancers</i> , 2022, 14, 2444.   | 3.7  | 2         |
| 11 | Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.                          | 3.1  | 1         |
| 12 | Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.                                     | 5.1  | 28        |
| 13 | Practice Variation in Skin Cancer Treatment and Follow-Up Care: A Dutch Claims Database Analysis. <i>Dermatology</i> , 2021, 237, 1000-1006.   | 2.1  | 6         |
| 14 | Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and Future. <i>HemaSphere</i> , 2021, 5, e524.  | 2.7  | 23        |
| 15 | Two decades of targeted therapies in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 651-660.  | 7.2  | 33        |
| 16 | A Systematic Review of Cost-Effectiveness Studies of Interventions With a Personalized Nutrition Component in Adults. <i>Value in Health</i> , 2021, 24, 325-335.  | 0.3  | 17        |
| 17 | Cost-effectiveness of Novel Treatment Sequences for Transplant-Ineligible Patients With Multiple Myeloma. <i>JAMA Network Open</i> , 2021, 4, e213497.   | 5.9  | 7         |
| 18 | Health-related quality of life of multiple sclerosis patients: a European multi-country study. <i>Archives of Public Health</i> , 2021, 79, 39.  | 2.4  | 21        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Real-world healthcare costs of localized and regionally advanced cutaneous melanoma in the Netherlands. <i>Melanoma Research</i> , 2021, 31, 249-257.   | 1.2 | 1         |
| 20 | Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach. <i>Cancers</i> , 2021, 13, 2308.   | 3.7 | 10        |
| 21 | Early technology assessment of using whole genome sequencing in personalized oncology. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021, 21, 343-351.   | 1.4 | 4         |
| 22 | Leveraging the Similarities Between Cost-Effectiveness Analysis and Value-Based Healthcare. <i>Value in Health</i> , 2021, 24, 1038-1044.   | 0.3 | 11        |
| 23 | Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer. <i>Pharmacoeconomics</i> , 2021, 39, 1429-1442.   | 3.3 | 10        |
| 24 | Stage-specific trends in incidence and survival of cutaneous melanoma in the Netherlands (2003-2018): A nationwide population-based study. <i>European Journal of Cancer</i> , 2021, 154, 111-119.  | 2.8 | 16        |
| 25 | Measurement Instruments of Productivity Loss of Paid and Unpaid Work: A Systematic Review and Assessment of Suitability for Health Economic Evaluations From a Societal Perspective. <i>Value in Health</i> , 2021, 24, 1686-1699.                                  | 0.3 | 21        |
| 26 | Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1-12.   | 2.4 | 1         |
| 27 | Adjuvant treatment in patients with melanoma: The planning of scanning. <i>European Journal of Cancer</i> , 2021, 157, 306-307.   | 2.8 | 1         |
| 28 | How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 336. | 3.0 | 2         |
| 29 | Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. <i>European Journal of Health Economics</i> , 2020, 21, 153-164.   | 2.8 | 30        |
| 30 | Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.   | 1.9 | 4         |
| 31 | Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. <i>Clinical Infectious Diseases</i> , 2020, 71, 3136-3143.  | 5.8 | 17        |
| 32 | Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab. <i>Breast</i> , 2020, 52, 71-77.                          | 2.2 | 11        |
| 33 | Cost of health care for paediatric patients with sickle cell disease: An analysis of resource use and costs in a European country. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28588.  | 1.5 | 5         |
| 34 | Economic evaluations of big data analytics for clinical decision-making: a scoping review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1466-1475.   | 4.4 | 15        |
| 35 | Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmacoeconomic assessment. <i>European Journal of Haematology</i> , 2020, 105, 635-645.  | 2.2 | 8         |
| 36 | Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 240.  | 2.4 | 4         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Response to Open Peer Commentary "Making It Count: Extracting Real World Data from Compassionate Use and Expanded Access Programs". American Journal of Bioethics, 2020, 20, W4-W5.  | 0.9 | 4         |
| 38 | Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. Cancers, 2020, 12, 2313.  | 3.7 | 33        |
| 39 | Assessment of Studies Evaluating Incremental Costs, Effectiveness, or Cost-Effectiveness of Systemic Therapies in Breast Cancer Based on Claims Data: A Systematic Review. Value in Health, 2020, 23, 1497-1508.             | 0.3 | 1         |
| 40 | Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer. Future Oncology, 2020, 16, 1371-1384.  | 2.4 | 25        |
| 41 | A clinician's guide for developing a prediction model: a case study using real-world data of patients with castration-resistant prostate cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2067-2075.     | 2.5 | 5         |
| 42 | Expanded Access as a source of real-world data: An overview of FDA and EMA approvals. British Journal of Clinical Pharmacology, 2020, 86, 1819-1826.   | 2.4 | 27        |
| 43 | CHANGING NURSING CARE TIME AS AN EFFECT OF CHANGED CHARACTERISTICS OF THE DIALYSIS POPULATION. Journal of Renal Care, 2020, 46, 161-168.   | 1.2 | 2         |
| 44 | Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study. Lung Cancer, 2020, 141, 89-96.                  | 2.0 | 15        |
| 45 | Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. Cancers, 2020, 12, 1003.   | 3.7 | 15        |
| 46 | Cost-effectiveness of Anti-CD19 chimeric antigen receptor T cell therapy in pediatric relapsed/refractory B cell acute lymphoblastic leukemia. A societal view. European Journal of Haematology, 2020, 105, 203-215.         | 2.2 | 29        |
| 47 | Fair Pricing of Innovative Medicines: An EHA Position Paper. HemaSphere, 2020, 4, e488.  | 2.7 | 6         |
| 48 | A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. European Journal of Cancer, 2019, 123, 58-71.  | 2.8 | 45        |
| 49 | Systematic reviews as a "lens of evidence": Determinants of cost-effectiveness of breast cancer screening. Cancer Medicine, 2019, 8, 7846-7858.  | 2.8 | 15        |
| 50 | What Is Next for Patient Preferences in Health Technology Assessment? A Systematic Review of the Challenges. Value in Health, 2019, 22, 1318-1328.   | 0.3 | 26        |
| 51 | Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical Genitourinary Cancer, 2019, 17, e946-e956. | 1.9 | 5         |
| 52 | &#x2013;First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis&#x2013;. OncoTargets and Therapy, 2019, Volume 12, 1413-1421.                                    | 2.0 | 51        |
| 53 | Stage-specific disease recurrence and survival in localized and regionally advanced cutaneous melanoma. European Journal of Surgical Oncology, 2019, 45, 825-831.  | 1.0 | 17        |
| 54 | Efficacy of first-line treatments for multiple myeloma patients not eligible for stem cell transplantation: a network meta-analysis. Haematologica, 2019, 104, 1026-1035.  | 3.5 | 17        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 55 | Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non-Small Cell Lung Cancer Using Real-World Data. <i>Value in Health</i> , 2019, 22, 322-331.  | 0.3  | 11        |
| 56 | A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27458.  | 1.5  | 14        |
| 57 | The Cost of Healthcare for Pediatric Patients with Sickle Cell Disease. <i>Blood</i> , 2019, 134, 1030-1030.  | 1.4  | 0         |
| 58 | Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.  | 1.4  | 11        |
| 59 | Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.   | 1.4  | 11        |
| 60 | Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe. <i>Pharmacogenomics</i> , 2018, 19, 213-226.  | 1.3  | 3         |
| 61 | Response to "Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy". <i>Pharmacoeconomics</i> , 2018, 36, 381-382. | 3.3  | 0         |
| 62 | Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2018, 4, 694-701.   | 3.1  | 43        |
| 63 | Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy. <i>Pharmacoeconomics</i> , 2018, 36, 91-103.                            | 3.3  | 26        |
| 64 | Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. <i>PLoS ONE</i> , 2018, 13, e0205079.   | 2.5  | 3         |
| 65 | Reply to "Response to proposal for a novel cancer drug pricing model". <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 528-529.   | 27.6 | 0         |
| 66 | Sustainability and affordability of cancer drugs: a novel pricing model. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 405-406.   | 27.6 | 55        |
| 67 | Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands. <i>Health Economics Review</i> , 2018, 8, 13.                            | 2.0  | 10        |
| 68 | Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model. <i>European Journal of Haematology</i> , 2018, 101, 676-683.  | 2.2  | 4         |
| 69 | Reply to "Economic comments on proposal for a novel cancer drug pricing model". <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 588-588.  | 27.6 | 1         |
| 70 | Potential cost savings owing to the route of administration of oncology drugs. <i>Anti-Cancer Drugs</i> , 2018, 29, 791-801.  | 1.4  | 23        |
| 71 | Long-term Outcomes in Patients With Multiple Myeloma. <i>HemaSphere</i> , 2018, 2, e45.   | 2.7  | 38        |
| 72 | Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands. <i>Blood</i> , 2018, 132, 3555-3555.        | 1.4  | 4         |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Balancing the Optimal and the Feasible: A Practical Guide for Setting Up Patient Registries for the Collection of Real-World Data for Health Care Decision Making Based on Dutch Experiences. <i>Value in Health</i> , 2017, 20, 627-636.   | 0.3  | 27        |
| 74 | A cost analysis of individualized asparaginase treatment in pediatric acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26651.   | 1.5  | 16        |
| 75 | Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks. <i>PLoS ONE</i> , 2017, 12, e0182613.   | 2.5  | 91        |
| 76 | A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model. <i>European Journal of Haematology</i> , 2016, 96, 198-208.  | 2.2  | 33        |
| 77 | Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1851-1859.   | 2.8  | 4         |
| 78 | THE EARLY BIRD CATCHES THE WORM: EARLY COST-EFFECTIVENESS ANALYSIS OF NEW MEDICAL TESTS. <i>International Journal of Technology Assessment in Health Care</i> , 2016, 32, 46-53.  | 0.5  | 32        |
| 79 | Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry. <i>Urology</i> , 2016, 95, 121-127.  | 1.0  | 34        |
| 80 | Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30. <i>Value in Health</i> , 2016, 19, 834-843. | 0.3  | 18        |
| 81 | Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands. <i>Leukemia Research</i> , 2016, 50, 37-45.  | 0.8  | 12        |
| 82 | Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2109-2110.   | 2.0  | 2         |
| 83 | Cost-effectiveness in colorectal cancer: challenges on quality and comparability. <i>Colorectal Cancer</i> , 2016, 5, 21-31.  | 0.8  | 3         |
| 84 | Experience with outcomes research into the real-world effectiveness of novel therapies in Dutch daily practice from the context of conditional reimbursement. <i>Health Policy</i> , 2015, 119, 186-194.  | 3.0  | 6         |
| 85 | Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer. <i>Value in Health</i> , 2015, 18, 84-90.   | 0.3  | 12        |
| 86 | Primary care in cancer control: towards mature cancer care. <i>Lancet Oncology</i> , The, 2015, 16, 1226-1227.  | 10.7 | 3         |
| 87 | Dispelling the myths around cancer care delivery: It's not all about costs. <i>Journal of Cancer Policy</i> , 2014, 2, 22-29.   | 1.4  | 25        |
| 88 | Policymaker, Please Consider Your Needs Carefully: Does Outcomes Research in Relapsed or Refractory Multiple Myeloma Reduce Policymaker Uncertainty Regarding Value for Money of Bortezomib?. <i>Value in Health</i> , 2014, 17, 245-253.   | 0.3  | 11        |
| 89 | The economics of improved cancer survival rates: better outcomes, higher costs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 283-292.  | 1.4  | 5         |
| 90 | Costs of haematological adverse events in chronic myeloid leukaemia patients: a retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia. <i>Journal of Medical Economics</i> , 2009, 12, 164-169.              | 2.1  | 14        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 91 | Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma. <i>Haematologica</i> , 2004, 89, 1109-17.                                  | 3.5 | 14        |
| 92 | Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin's Lymphoma. <i>Pharmacoeconomics</i> , 1999, 15, 305-311. | 3.3 | 10        |
| 93 | Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations. <i>Frontiers in Pharmacology</i> , 0, 13, .  | 3.5 | 11        |